Core Insights - Norges Bank increased its stake in Kelaiying (002821)(06821) by acquiring 62,300 shares at a price of HKD 84.5083 per share, totaling approximately HKD 5.2649 million [1] - Following this transaction, Norges Bank's total shareholding in Kelaiying reached 3.8883 million shares, representing a 14.11% ownership stake [1]

Core Insights - Norges Bank increased its stake in Kairong (06821) by acquiring 62,300 shares at a price of HKD 84.5083 per share, totaling approximately HKD 5.2649 million [1] - Following this acquisition, Norges Bank's total shareholding in Kairong reached 3.8883 million shares, representing a 14.11% ownership stake [1]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][20] Core Views - The company achieved steady growth in the first three quarters of 2025, with revenue reaching 4.63 billion yuan (+11.82%) and net profit attributable to shareholders at 800 million yuan (+12.66%) [1][6] - Emerging businesses are becoming the core growth engine, with a significant increase in revenue from new business areas, particularly in chemical macromolecules, which saw over 150% growth [2][3] - The company is expected to maintain rapid revenue growth throughout 2025, with projected revenues of 6.68 billion yuan, 7.53 billion yuan, and 8.29 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 15%, 13%, and 10% [3][4] Financial Performance Summary - For the first three quarters of 2025, the company reported quarterly revenues of 1.54 billion yuan, 1.65 billion yuan, and 1.44 billion yuan for Q1, Q2, and Q3 respectively, with Q2 showing the highest growth at +26.95% [1][6] - The operating cash flow improved to 1.144 billion yuan (+8.38%), indicating enhanced operational efficiency and effective cost control [2][12] - The gross margin for the small molecule CDMO business was 47.0% (-1.9pp), while the emerging business gross margin was 30.6% (+10.6pp) [2][3] Earnings Forecast - The company forecasts net profits of 1.14 billion yuan, 1.29 billion yuan, and 1.46 billion yuan for 2025, 2026, and 2027 respectively, with expected growth rates of 20%, 14%, and 14% [3][4] - The current price-to-earnings ratio (PE) is projected to be 29.8, 26.3, and 23.1 for the years 2025, 2026, and 2027 respectively [3][4]

Group 1 - JPMorgan Chase & Co. increased its stake in Kelaiying (06821.HK) by acquiring 155,800 shares at an average price of HKD 82.7632 per share, totaling approximately HKD 12.89 million [1] - Following this acquisition, JPMorgan's total holdings in Kelaiying rose to 2,326,842 shares, increasing its ownership percentage from 7.87% to 8.44% [1][2]

Group 1 - JPMorgan Chase & Co. increased its stake in Kailaiying (06821.HK) by purchasing 155,800 shares at an average price of HKD 82.7632 per share, totaling approximately HKD 12.8945 million [1] - Following this transaction, JPMorgan's total holdings in Kailaiying rose to 2,326,842 shares, increasing its ownership percentage from 7.87% to 8.44% [1]

Core Viewpoint - Morgan Stanley increased its stake in Kelaiying (002821)(06821) by 155,800 shares at a price of HKD 82.7632 per share, totaling approximately HKD 12.8945 million, raising its total holdings to about 2.3268 million shares, which represents a holding percentage of 8.44% [1] Summary by Category - **Investment Activity** - Morgan Stanley's recent purchase of 155,800 shares indicates a strategic move to increase its investment in Kelaiying [1] - The total investment amount for this transaction was approximately HKD 12.8945 million [1] - **Shareholding Details** - Following the increase, Morgan Stanley's total shareholding in Kelaiying is now approximately 2.3268 million shares [1] - The updated shareholding percentage stands at 8.44% [1]

Group 1 - Morgan Stanley increased its stake in Kairui Ying (06821) by 155,800 shares at a price of HKD 82.7632 per share, totaling approximately HKD 12.8945 million [1] - After the increase, the total number of shares held by Morgan Stanley is approximately 2.3268 million, representing a holding percentage of 8.44% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | 備註： 第 1 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 本月底法定/註冊股本總額： RMB 360,593,720 備註： 第 1 頁 共 11 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, particularly recommending a focus on innovative drugs and sectors with improving performance such as medical devices and CXO [1][10]. Core Insights - The pharmaceutical sector in Q3 2025 showed signs of recovery with a year-on-year revenue growth of 0.6% in Q3, marking the first positive growth in four quarters [1][10]. - Innovative drugs demonstrated a remarkable revenue growth of 36% in Q3 2025, with a turnaround in net profit from a loss of 500 million to a profit of 1.5 billion [10]. - The CXO sector also showed strong performance with a revenue growth of 10.9% and a net profit increase of 47.7% year-on-year, indicating a trend reversal [10]. Summary by Sections Q3 2025 Performance - The A-share pharmaceutical sector, excluding certain companies, achieved total revenue of 1,806.4 billion with a year-on-year decline of 1.9% and a net profit of 139.2 billion, down 5.1% year-on-year [2][11]. - In Q3 2025, total revenue reached 600.4 billion, reflecting a year-on-year increase of 0.6% but a quarter-on-quarter decrease of 0.4% [2][11]. Profitability and Margins - The gross profit for the pharmaceutical sector in Q3 2025 was 189.1 billion, with a gross margin of 31.5%, slightly down from the previous year [5][8]. - The overall net profit margin for Q3 2025 was 6.8%, showing a slight decline compared to the previous year [8]. Cash Flow - The sector reported a net cash inflow from operating activities of 59.1 billion in Q3 2025, representing a year-on-year growth of 17.9% [7][13]. Subsector Performance - The innovative drug sector's revenue growth of 36% and the CXO sector's revenue growth of 10.9% highlight the strong recovery and growth potential within these subsectors [10][11]. - The report emphasizes the importance of focusing on companies such as 恒瑞医药, 长春高新, and 药明康德, which are expected to perform well in the current market environment [1][10].